Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic FunctionSuleiman Massarweh, Rachel Schiff, C. Kent Osborne et al.|Cancer Research|2008Cited by 494
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft ModelsXiaomei Zhang, Michael T. Lewis, Sofie Claerhout et al.|Cancer Research|2013Cited by 485
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET TrialStephen Johnston, Samuel A. Jacobs, Shannon Puhalla et al.|Journal of Clinical Oncology|2018Cited by 233
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancerXiaoyong Fu, Rachel Schiff, Rinath Jeselsohn et al.|Proceedings of the National Academy of Sciences|2016Cited by 185
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 BlockadeAleix Prat, Mothaffar F. Rimawi, Tomás Pascual et al.|JNCI Journal of the National Cancer Institute|2019Cited by 168